Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
Operational updates
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema
Operational updates
Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer
Operational updates
Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain
Operational updates
Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors
Operational updatesPharming Group announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Their official appointments will be confirmed by the Company’s Annual General Meeting of Shareholders that will be held on 19 May 2021.
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’ in US and Canada
Operational updatesNew program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease
Juergen Ernst to retire from Pharming’s Board of Supervisory Directors after more than 11 years of distinguished service
Operational updatesPharming Group N.V. today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair.
Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®
Operational updatesPharming Group N.V. announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).
Pharming appoints Jeroen Wakkerman as Chief Financial Officer
Operational updatesPharming Group N.V. announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.
Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
Operational updatesPharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).